Business Wire

STV to Deploy Post-Quantum’s Secure Communications Platform, Forms Strategic Cooperation to Deliver Next-Generation Security

4.11.2025 10:00:00 CET | Business Wire | Press Release

Share

STV Group a.s. (“STV”), one of the world’s fastest-growing defence innovators, has signed a multi-year licence agreement to use Post-Quantum’s groundbreaking quantum-safe communications platform and signed a Strategic Cooperation Agreement to accelerate deployment across Europe, NATO, and global defence markets. With quantum computing threatening to render traditional encryption obsolete, the move positions STV at the forefront of the cybersecurity revolution - arming governments, defence forces, and enterprises with next-generation resilience against “Harvest Now, Decrypt Later” attacks.

By fusing Post-Quantum’s NATO-tested modular platform with its own world-class defence solutions, STV is setting a new global benchmark for secure communications and digital trust. Together, the two companies are delivering the most advanced, future-proof systems to protect sensitive data and mission-critical operations - ensuring that even in the quantum era, allied communications remain impenetrable.

The partnership represents a decisive leap forward, combining STV’s defence innovation track record with Post-Quantum’s pioneering expertise to deliver communications and data protection systems that go beyond current industry standards.

JUDr. Pavel Kudrhalt, CEO of STV, said: “This isn’t just about acquiring technology - it’s about building an uncompromising, end-to-end secure ecosystem for the future. Our customers demand full supply chain assurance, from manufacturing and tamper-proof transport to deployment and monitoring. With the rising threat of ‘Harvest Now, Decrypt Later’ attacks, quantum-safe defences are no longer optional. Post-Quantum’s platform doesn’t just lead the field - it allows STV to be the first-mover to redefine the very standards of digital trust in defence solutions. By embedding their technology into our portfolio, we are giving NATO allies, EU partners, and national clients the strongest possible protection for the quantum era - whether that’s safeguarding command and control chains, operating mission-critical drones, or deploying munitions in battlefield communications.”

Rikky Hasan, CEO of Post-Quantum, added: “STV’s vision and leadership in defence innovation make them the ideal partner. Together we are unleashing a new wave of secure, quantum-safe solutions that protect the world’s most sensitive data against today’s adversaries and tomorrow’s quantum threats. Our modular approach to Identity, Transmission and Encryption - already proven in NATO environments - offers the fastest and most agile way to integrate into STV’s global portfolio. This is a proud moment for both companies, and a milestone for global cybersecurity.”

This acquisition and alliance signal the dawn of a new era: one where quantum-resilient platforms are no longer optional, but essential. United by a shared mission to safeguard the future, STV and Post-Quantum are leading the charge toward a world where critical communications remain impenetrable - even in the face of quantum computing’s disruptive power.

About STV

STV Group a.s. is one of Europe’s fastest-growing defence innovators, delivering advanced security and defence solutions to governments, NATO allies, and commercial partners worldwide. Headquartered in the Czech Republic, the company combines cutting-edge engineering with a bold vision for the future of security.

Building on a century of industrial tradition, STV Group has become the Czech Republic’s leading producer of munitions, loitering systems, armoured vehicle platforms and integrated lifecycle services. The group is also a European leader in ecological disposal and demilitarisation of surplus ammunition, underscoring its commitment to safety and sustainability. With NATO-tested technologies and global partnerships, STV Group is trusted to deliver the resilient, future-proof capabilities that keep nations secure in an era of emerging threats.

About Post-Quantum

Post-Quantum is leading the charge into the quantum era by upgrading the world’s encryption. Its quantum-safe platform protects organisations across their entire digital footprint with modular software for Identity, Transmission, and Encryption—designed to be interoperable, crypto-agile and seamlessly backward compatible.

Already trusted by NATO, critical national infrastructure providers, and major financial institutions, Post-Quantum has a proven track record in safeguarding mission-critical data. The company is the inventor of NTS-KEM (now known as Classic McEliece in the NIST competition) and the author of the IETF’s Hybrid Post-Quantum VPN standard, which is now the global benchmark for secure connectivity. With its pioneering technologies, Post-Quantum is ensuring the world stays one step ahead of the quantum threats.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104052022/en/

Contacts

For further information, please contact:
Fire on the Hill
Nick Ward. +44 (0)7821 474 272
nward@fireoth.com
postquantum@fireoth.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye